Search This Blog

Wednesday, July 29, 2026

RMAT and Fast Track to Allogene in large B-cell lymphoma

 FDA grants RMAT and Fast Track to Allogene's allogeneic CAR-T cemacabtagene ansegedleucel for high-risk large B-cell lymphoma

  • Cemacabtagene ansegedleucel is being developed as first-line consolidation therapy for high-risk large B-cell lymphoma.
  • Designations are based on interim futility data from the pivotal ALPHA3 trial of cemacabtagene ansegedleucel.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)